Bacil Pharma Q1 FY27: Loss of 1.61L vs 89.40L profit YoY, nil operating revenue
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.1 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bacil Pharma posted Q1 FY27 results with nil operating revenue and only 8.91 lakh of other income, down sharply from 100.30 lakh YoY. PAT from ordinary activities swung to a loss of 1.61 lakh versus a profit of 66.90 lakh last year. Total profit for the period stood at 30.12 lakh after including 31.73 lakh of other comprehensive income. EPS came in at 0.22 versus 0.48. Auditor issued a clean limited review with no qualifications.
Sharp income drop and swing to operating loss signal weak core business; bottom line was rescued by OCI gains rather than operations.